Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission

被引:60
|
作者
Polter, Abigail M. [1 ]
Li, Xiaohua [1 ]
机构
[1] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA
来源
FRONTIERS IN MOLECULAR NEUROSCIENCE | 2011年 / 4卷
关键词
serotonin; GSK3; 5-HT1A; 5-HT1B; 5-HT2A; antidepressants; MAJOR DEPRESSIVE DISORDER; ACTIVATED PROTEIN-KINASE; RECEPTOR-MEDIATED INHIBITION; DEPENDENT CELL-SURVIVAL; FORCED SWIMMING TEST; 5-HT1B RECEPTORS; DOUBLE-BLIND; PREFRONTAL CORTEX; REGULATED KINASE; ANIMAL-MODEL;
D O I
10.3389/fnmol.2011.00031
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Serotonin is a neurotransmitter with broad functions in brain development, neuronal activity, and behaviors; and serotonin is the prominent drug target in several major neuropsychiatric diseases. The multiple actions of serotonin are mediated by diverse serotonin receptor subtypes and associated signaling pathways. However, the key signaling components that mediate specific function of serotonin neurotransmission have not been fully identified. This review will provide evidence from biochemical, pharmacological, and animal behavioral studies showing that serotonin regulates the activation states of brain glycogen synthase kinase-3 (GSK3) via type 1 and type 2 serotonin receptors. In return, GSK3 directly interacts with serotonin receptors in a highly selective manner, with a prominent effect on modulating serotonin 1B receptor activity. Therefore, GSK3 acts as an intermediate modulator in the serotonin neurotransmission system, and balanced GSK3 activity is essential for serotonin-regulated brain function and behaviors. Particularly important, several classes of serotonin-modulating drugs, such as antidepressants and atypical antipsychotics, regulate GSK3 by inhibiting its activity in brain, which reinforces the importance of GSK3 as a potential therapeutic target in neuropsychiatric diseases associated with abnormal serotonin function.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of Enzastaurin
    Rovedo, Mark A.
    Krett, Nancy L.
    Rosen, Steven T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (07) : 1442 - 1449
  • [42] Glycogen Synthase Kinase-3 Inhibition: Good or Bad for the Heart?
    Lochner, Amanda
    Flepisi, Brian
    Huisamen, Barbara
    CIRCULATION, 2013, 128 (22)
  • [43] Construction of the pharmacophore model of glycogen synthase kinase-3 inhibitors
    Liu, Ling
    Zhang, Li-Na
    Jiang, Feng-Chao
    CHINESE JOURNAL OF CHEMISTRY, 2007, 25 (07) : 892 - 897
  • [44] THE ROLE OF GLYCOGEN SYNTHASE KINASE-3 IN LIMB DEVELOPMENT AND PATTERNING
    Aubrey, L. A.
    Gillespie, J. R.
    Bush, J. R.
    Beier, F.
    OSTEOARTHRITIS AND CARTILAGE, 2013, 21 : S134 - S135
  • [45] Glycogen synthase kinase-3β is highly activated in nuclei and mitochondria
    Bijur, GN
    Jope, RS
    NEUROREPORT, 2003, 14 (18) : 2415 - 2419
  • [46] Phosphoproteomics links glycogen synthase kinase-3 to RNA splicing
    Le Tran Phuc Khoa
    Dou, Yali
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (44) : 18256 - 18257
  • [47] The insulin mimetic action of Glycogen Synthase Kinase-3 inhibitors
    Eldar-Finkelman, H
    Kaidanovich, O
    Plotkin, B
    Talior, I
    DIABETOLOGIA, 2002, 45 : A70 - A70
  • [48] Regulation of glycogen synthase kinase-3 in patients with affective disorders
    O'Brien, W. Timothy
    Klein, Peter S.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (02) : 139 - 141
  • [49] Glycogen synthase kinase-3 as a key regulator of cognitive function
    Fan, Xuhong
    Zhao, Zhenyu
    Wang, Deming
    Xiao, Ji
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (03) : 219 - 230
  • [50] Screening of inhibitors of Taenia solium glycogen synthase Kinase-3β
    Wang, Li
    Cheng, Jiagao
    Wang, Shuai
    Zhang, Xichen
    Cai, Xuepeng
    RSC ADVANCES, 2017, 7 (68): : 43319 - 43326